| Description |
Comparative effectiveness has been one of the most contentious issues in health reform. Recent legislative initiatives and current health reform proposals have moved comparative effectiveness to the forefront of attention for health care stakeholders, with a broad range of complexities and implications.
Generating better evidence about the costs and benefits of different treatment options – through research on the comparative effectiveness of those options – has the potential to bend the curve in health care spending and reduce inappropriate variation in the system.
Join Paul Keckley, Executive Director of the Deloitte Center for Health Solutions, Deloitte LLP, in an examination of comparative effectiveness implications for a variety of stakeholders, including policy makers, providers, consumers, payors/health plans, and life sciences companies, based upon the recent Deloitte Center for Health Solutions study: "Comparative Effectiveness: Perspectives for Consideration." Report findings conclude that, in the U.S., a “tools, not rules” approach, with industry and policy makers working side by side, will result in a comparative effectiveness model that delivers better value and lower costs.
|
|
